The extended clearance model and its use for the interpretation of hepatobiliary elimination data by Gian Camenisch, Julia Riede, Annett Kunze, Jörg Huwyler, Birk Poller, Kenichi Umehara

Connect to this object online.

Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling by Felix Huth, Hilmar Schiller, Yi Jin, Birk Poller, Carole Schuhler, Wendy Weis, Ralph Woessner, Anton Drollmann, Peter End

Connect to this object online.

The application of organ-on-chip models for the prediction of human pharmacokinetic profiles during drug development by Marit Keuper-Navis, Markus Walles, Birk Poller, Adam Myszczyszyn, Thomas K. van der Made, Joanne Donkers, Hossein Eslami Amirabadi, Martijn J. Wilmer, Saskia Aan, Bart Spee, Rosalinde Masereeuw, Evita van de Steeg

Connect to this object online.

LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial by Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H. Markus Weiss, Heike Otto, Martin Fink, Till A. Röhn

Connect to this object online.